- EvidenceScore™
- Strong
- Score 79 · Based on 4 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 75
- consistent
Linagliptin may increase postprandial renal hyperfiltration in type 2 diabetes
Última actualización 2 de septiembre de 2026
Key finding
Linagliptin increased the postprandial filtration fraction (FF; mean difference 2.1% point; P = .016)
This study evaluated the effects of linagliptin on renal function in adults with type 2 diabetes, finding significant improvements in certain renal parameters.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of linagliptin on renal function in adults with type 2 diabetes, finding significant improvements in certain renal parameters.
Clinical relevance
Understanding the effects of these medications on kidney function is crucial for managing diabetes, as renal health is often compromised in diabetic patients. The findings suggest that while linagliptin may help improve kidney function, glimepiride remains a stronger option for controlling blood sugar levels.
Keep in mind
Unclear effectiveness for some outcomes. Limited generalizability due to specific population characteristics. Small sample size may affect the robustness of findings.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Marcel HAM, Lennart T, Mark MS, et al. The effect of linagliptin on postprandial renal haemodynamics in adults with type 2 diabetes: a randomized controlled trial. Diabetes, Obesity & Metabolism. 2021;24(1):115-124. doi:10.1111/dom.14557
Efectos Principales
Linagliptin increased postprandial filtration fraction by 2.1% (P = .016).
Linagliptin increased estimated glomerular hydraulic pressure by 3.0 mmHg (P = .050).
Glimepiride reduced HbA1c by 0.40% more than linagliptin (P = .004).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Glimepiride, Linagliptin 5 mg and HbA1c, Estimated glomerular hydraulic pressure increase, Glomerular filtration rate (GFR), and 2 more.
This study contributes evidence to
Primary intervention
Glimepiride
Primary outcomes
- HbA1c
- Estimated glomerular hydraulic pressure increase
- Glomerular filtration rate (GFR)
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
4
Related topics
5
Evidence pairs
1053
Related studies
Why it is useful
- Contributes to 5 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Sulfonylureas and HbA1c
Evidencia relacionada
Tema de evidencia
Glycemic Control
Guardar evidencia
Tema de evidencia
HbA1c Reduction
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Estimated glomerular hydraulic pressure increase
Linagliptin 5 mg → Estimated glomerular hydraulic pressure increase
Linagliptin 5 mg → Estimated glomerular hydraulic pressure increase
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Glomerular filtration rate (GFR)
Linagliptin 5 mg → Glomerular filtration rate (GFR)
Linagliptin 5 mg → Glomerular filtration rate (GFR)
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Postprandial blood glucose
Linagliptin 5 mg → Postprandial blood glucose
Linagliptin 5 mg → Postprandial blood glucose
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Postprandial filtration fraction increase
Linagliptin 5 mg → Postprandial filtration fraction increase
Linagliptin 5 mg → Postprandial filtration fraction increase
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Linagliptin improved filtration fraction by 2.1%.
- Estimated glomerular hydraulic pressure increased by 3 mmHg with linagliptin.
- Glimepiride reduced HbA1c by 0.40% more effectively than linagliptin.
A quién se aplica
- Adults diagnosed with type 2 diabetes.
- Patients requiring medication for blood sugar control.
Tener en Cuenta
- Results may not apply to populations outside the study group.
- Further research needed to confirm long-term effects.
- Statistical significance does not always imply clinical relevance.
Entre Líneas
- Unclear effectiveness for some outcomes.
- Limited generalizability due to specific population characteristics.
- Small sample size may affect the robustness of findings.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Sulfonylureas and HbA1c, Linagliptin 5 mg and Estimated glomerular hydraulic pressure increase.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Sulfonylureas → HbA1c
Medications
- EvidenceScore™
- Strong
- Score 79 · Based on 4 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 75
- consistent
Linagliptin 5 mg → Estimated glomerular hydraulic pressure increase
Diet and Nutrition
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Incluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
Measures HbA1c as a key outcome.
Sulfonylureas Evidence Hub
All studies on Sulfonylureas
Contributes to Sulfonylureas evidence base.
Estimated glomerular hydraulic pressure increase Evidence Hub
All studies measuring Estimated glomerular hydraulic pressure increase
Measures Estimated glomerular hydraulic pressure increase as a key outcome.
Linagliptin 5 mg Evidence Hub
All studies on Linagliptin 5 mg
Contributes to Linagliptin 5 mg evidence base.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Glimepiride and HbA1c
4 results
All studies on Linagliptin 5 mg and Estimated glomerular hydraulic pressure increase
1 results
All studies on Glimepiride
4 results
All studies on Linagliptin 5 mg
1 results
All studies measuring HbA1c
4 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Do Sulfonylureas lower HbA1c?
Sulfonylureas may lower HbA1c.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 7 supporting studies with generally consistent results and a positive effect signal.
What evidence is available on Linagliptin 5 mg and estimated glomerular hydraulic pressure increase?
Linagliptin 5 mg appears to improve estimated glomerular hydraulic pressure increase.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Estimated glomerular hydraulic pressure increase
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
What evidence is available on Linagliptin 5 mg and postprandial filtration fraction increase?
Linagliptin 5 mg appears to improve postprandial filtration fraction increase.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Postprandial filtration fraction increase
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Linagliptin 5 mg improve glomerular filtration rate (GFR)?
Current evidence does not show a clear benefit of Linagliptin 5 mg for glomerular filtration rate (GFR).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Glomerular filtration rate (GFR)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.
